Availability and affordability of treatment for Human African Trypanosomiasis.

Hdl Handle:
http://hdl.handle.net/10144/16877
Title:
Availability and affordability of treatment for Human African Trypanosomiasis.
Authors:
Etchegorry, M; Helenport, J; Pecoul, B; Jannin, J; Legros, D
Journal:
Tropical Medicine & International Health
Abstract:
Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance. Availability of HAT drugs is poor and their production in danger because of technical, ecological and economic constraints. In view of this dramatic situation, a network involving experts from NGOs, WHO and pharmaceutical producers was commissioned with updating estimates of need for each HAT drug for the coming years; negotiations with potential producers of new drugs such as eflornithine; securing sustainable manufacturing of existing drugs; clinical research into new combinations of these drugs for first and second-line treatments; centralizing drug purchases and their distribution through a unique non-profit entity; and addressing regulatory and legal issues concerning new drugs.
Affiliation:
Médecins Sans Frontières, 8 Rue Saint Sabin, Paris.
Publisher:
Wiley-Blackwell
Issue Date:
Nov-2001
URI:
http://hdl.handle.net/10144/16877
PubMed ID:
11703853
Additional Links:
http://www.blackwell-synergy.com/loi/tmi
Language:
en
ISSN:
1360-2276
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorEtchegorry, M-
dc.contributor.authorHelenport, J-
dc.contributor.authorPecoul, B-
dc.contributor.authorJannin, J-
dc.contributor.authorLegros, D-
dc.date.accessioned2008-01-25T15:50:00Z-
dc.date.available2008-01-25T15:50:00Z-
dc.date.issued2001-11-
dc.identifier.citationAvailability and affordability of treatment for Human African Trypanosomiasis. 2001, 6 (11):957-9 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276-
dc.identifier.pmid11703853-
dc.identifier.urihttp://hdl.handle.net/10144/16877-
dc.description.abstractHuman African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance. Availability of HAT drugs is poor and their production in danger because of technical, ecological and economic constraints. In view of this dramatic situation, a network involving experts from NGOs, WHO and pharmaceutical producers was commissioned with updating estimates of need for each HAT drug for the coming years; negotiations with potential producers of new drugs such as eflornithine; securing sustainable manufacturing of existing drugs; clinical research into new combinations of these drugs for first and second-line treatments; centralizing drug purchases and their distribution through a unique non-profit entity; and addressing regulatory and legal issues concerning new drugs.en
dc.language.isoenen
dc.publisherWiley-Blackwell-
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi-
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen
dc.subject.meshEflornithineen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHumansen
dc.subject.meshMelarsoprolen
dc.subject.meshPentamidineen
dc.subject.meshResearchen
dc.subject.meshSuraminen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosomiasis, Africanen
dc.subject.meshWorld Health Organizationen
dc.titleAvailability and affordability of treatment for Human African Trypanosomiasis.en
dc.contributor.departmentMédecins Sans Frontières, 8 Rue Saint Sabin, Paris.en
dc.identifier.journalTropical Medicine & International Healthen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.